Paget Disease Treatment Market Size, Share, and Growth Forecast, 2026 - 2033

The global paget disease treatment market size is likely to be valued at US$2.0 billion in 2026 and is expected to reach US$2.9 billion by 2033, growing at a CAGR of 5.5% between 2026 and 2033, driven by population aging, greater recognition of Paget disease, continued use of bisphosphonates, and increasing access to specialized bone-health services.

Paget disease treatment remains centered on established antiresorptive therapies rather than rapid pharmaceutical innovation. Zoledronic acid has a particularly important position because of its potency, convenient dosing schedule, and established clinical efficacy. At the same time, opportunities are emerging around earlier diagnosis, genetic risk assessment, improved patient identification, treatment of skeletal complications, and wider access to affordable therapies in developing healthcare markets.

Drivers - Aging Population Expands the Addressable Patient Pool

Population aging represents a structural driver for the Paget disease treatment market because the condition occurs predominantly among older adults. The global population aged 60 years and older is expected to increase from approximately 1.0 billion in 2020 to 1.4 billion by 2030 and 2.1 billion by 2050. Paget disease is uncommon before the age of 50 and becomes considerably more prevalent among older populations. U.S. imaging studies have reported pelvic Paget disease in approximately 2.32% of individuals aged 65-74, illustrating the relationship between advancing age and disease prevalence.

The commercial impact of aging should, however, be assessed alongside long-term epidemiological changes. Paget disease prevalence has declined in several historically high-prevalence countries, particularly in parts of Europe.

Consequently, demographic aging is expected to support the addressable patient population and sustain treatment demand rather than produce a proportionate increase in incidence. Greater healthcare utilization among older adults also increases opportunities for incidental identification through imaging, biochemical testing, and orthopedic evaluation. Pharmaceutical companies and healthcare providers can therefore benefit from stronger integration of Paget disease screening into geriatric, endocrinology, rheumatology, and orthopedic care pathways.

Established Role of Bisphosphonates Supports Treatment Demand

The established clinical position of bisphosphonates provides another important foundation for market growth. Clinical guidelines recommend bisphosphonates for Paget-associated bone pain, with zoledronic acid generally favored because of its high potency and durable suppression of abnormal bone remodeling. U.S. prescribing information specifies a single 5 mg intravenous dose for appropriately selected adults with Paget disease. Oral bisphosphonates such as risedronate remain alternatives for patients who cannot receive intravenous treatment or where oral therapy is clinically appropriate.

This treatment model creates recurring demand across pharmaceutical manufacturing, hospital procurement, specialty clinics, laboratory testing, and infusion services. The long duration of response associated with zoledronic acid also provides a practical advantage because patients may not require frequent dosing. Consequently, market expansion is less dependent on frequent treatment cycles and more closely linked to disease identification, treatment eligibility, healthcare access, and product availability. Manufacturers with reliable injectable supply chains and competitive generic portfolios can benefit from the established role of bisphosphonate therapy while expanding access in cost-sensitive markets.

Restraint - Low Disease Prevalence, Underdiagnosis, and Treatment Restrictions Limit Market Expansion

The relatively low prevalence of Paget disease in many countries represents a fundamental constraint on market size. The condition is particularly uncommon across much of Asia, while many affected patients remain asymptomatic and may never receive a definitive diagnosis. A Japanese epidemiological survey identified only 169 patients, demonstrating the comparatively small diagnosed population in some Asian markets.

Treatment-related considerations further restrict utilization. Intravenous zoledronic acid requires assessment of renal function, adequate hydration, and appropriate monitoring. Clinical studies have also reported acute-phase reactions and reductions in serum calcium following treatment. Calcitonin provides an alternative for selected patients but is subject to safety considerations and periodic reassessment. These factors increase clinical screening requirements and can restrict treatment among patients with renal impairment, hypocalcemia, or other contraindications. The result is a market in which clinical eligibility and diagnosis represent greater constraints than pharmaceutical availability alone.

Opportunities - Genetic Risk Assessment Creates Potential for Earlier Disease Identification

Genetic research provides an emerging opportunity to improve identification of individuals at elevated risk of Paget disease. The condition has a recognized hereditary component, with SQSTM1 among the genes associated with susceptibility. Research involving genetically predisposed individuals has evaluated whether genetic testing followed by targeted treatment could reduce disease progression.

The ZiPP randomized trial included 222 mutation carriers and evaluated early zoledronic acid treatment. Although the study was not sufficiently powered to establish preventive treatment as a universal standard of care, its findings demonstrated reduced biochemical markers of bone turnover and provided evidence supporting further investigation of genetically targeted approaches.

The commercial implications extend beyond pharmaceuticals. Genetic testing, specialist referral, bone imaging, biochemical monitoring, and long-acting antiresorptive treatment could increasingly form an integrated diagnostic and treatment pathway. If further clinical evidence validates risk-directed intervention, manufacturers and diagnostic providers could address patients before substantial skeletal damage develops. Such a model would shift part of market activity from late-stage symptomatic treatment toward earlier risk identification and disease management.

Asia Pacific Offers Demographic and Pharmaceutical Manufacturing Opportunities

Asia Pacific represents an important long-term opportunity despite the historically low prevalence of Paget disease in many Asian countries. China is expected to have approximately 402 million people aged 60 and older by 2040, representing around 28% of its population. India had approximately 156.7 million people aged 60 and older in 2024, and the proportion is expected to reach approximately 21% by 2050.

These demographic changes do not imply equivalent growth in Paget disease incidence, but they enlarge the population requiring evaluation for age-related skeletal conditions. Rising healthcare expenditure, improved imaging availability, and specialist access can gradually increase disease recognition.

India also offers a major pharmaceutical manufacturing advantage. The country ranks among the world's largest pharmaceutical producers by volume and supplies approximately 20% of global generic medicine demand. Government-supported initiatives have expanded domestic production of active pharmaceutical ingredients, drug intermediates, and finished medicines. This creates opportunities for cost-efficient production of zoledronic acid, other bisphosphonates, calcitonin, and supportive therapies. Regional manufacturers can also use India as an export base for emerging markets where affordability and reliable supply remain key purchasing considerations.

Treatment Type Insights

Bisphosphonates are anticipated to account for 48.3% of the market share in 2026. Their position reflects established clinical use and their ability to suppress excessive osteoclast activity responsible for abnormal bone remodeling. The category includes zoledronic acid, risedronate, and pamidronate. Zoledronic acid is the principal therapeutic option because of its high potency and single-infusion dosing, which can improve convenience for older patients. Its established use in the U.S. and Europe further supports demand in specialist and hospital settings.

Zoledronic acid is anticipated to be the fastest-growing major drug segment, supported by strong efficacy, prolonged suppression of bone turnover, and the convenience of a single 5 mg intravenous treatment in appropriate patients. Oral bisphosphonates remain important where infusion facilities are limited, while calcitonin provides an alternative for selected patients unable to receive bisphosphonates. Analgesics and anti-inflammatory drugs, such as NSAIDs, support pain management, while calcium and vitamin D supplements provide supportive care where clinically indicated. The segment therefore combines disease-modifying therapies with symptom-management and supportive treatments.

Disease Manifestation or Treatment Objective

Bone pain management is anticipated to hold 50.3% of market share in 2026, as pain is a major reason patients with Paget disease seek medical attention. Pain may result directly from increased bone turnover or from secondary osteoarthritis, deformity, and altered biomechanics. Bisphosphonate therapy is widely used for Paget-related bone pain, making symptom relief a key treatment objective. Examples include managing persistent pain in the pelvis, spine, skull, or weight-bearing bones affected by Pagetic remodeling.

Prevention of skeletal complications is anticipated to be the fastest-growing application segment, supported by greater emphasis on early disease recognition and complication control. Advanced Paget disease can contribute to fractures, deformity, osteoarthritis, hearing impairment, and nerve compression. Management of joint complications, including Paget-associated hip or knee osteoarthritis, also represents an important application. Neurological and sensory complications may require multidisciplinary care, while preoperative and postoperative treatment can support patients undergoing orthopedic procedures for fractures, deformities, or advanced joint disease.

North America Paget Disease Treatment Market Trends

North America is the leading regional market for Paget disease treatment, accounting for an estimated 38.5% of global revenue. Its position reflects historically higher disease prevalence, an aging population, specialist care, advanced diagnostics, and high healthcare expenditure.

U.S. Paget Disease Treatment Market Trends

The U.S. is the largest market, supported by approximately 61.2 million people aged 65 and older in 2024, or about 18% of the population. Zoledronic acid remains central to treatment, supported by an established regulatory pathway covering renal function, hydration, calcium and vitamin D status, and infusion administration. A notable development occurred in February 2025, when Fresenius Kabi launched Calcitonin Salmon Injection, USP Synthetic for symptomatic Paget disease when alternative treatments are unsuitable. The product, manufactured and packaged in the U.S., expands availability of a non-bisphosphonate option and strengthens the country's generic injectable supply base.

Canada Paget Disease Treatment Market Trends

Canada represents a smaller but established market, supported by an aging population, specialist healthcare infrastructure, and availability of injectable bisphosphonate therapy. Fresenius Kabi's zoledronic acid injection is commercially available in Canada as a bone-metabolism regulator, supporting access to established infusion-based treatment. The market remains focused on reliable generic supply, specialist diagnosis, and management of complications such as bone pain and osteoarthritis.

Europe Paget Disease Treatment Market Trends

Europe is an established market, particularly across the U.K., Germany, France, and Spain. Historical prevalence has been comparatively high in parts of the region, although prevalence has declined in several populations. Mature healthcare infrastructure, specialist expertise, and established bisphosphonate treatment pathways support continued demand.

United Kingdom Paget Disease Treatment Market Trends

The U.K. remains an important clinical market because Paget disease is well recognized and treatment guidance is established. Zoledronate is a major treatment option, while oral bisphosphonates provide alternatives for selected patients. The aging population supports demand, although declining disease prevalence limits faster expansion. Competition increasingly centers on cost efficiency, generic availability, and reliable pharmaceutical supply rather than new Paget-specific mechanisms.

Germany Paget Disease Treatment Market Trends

Germany combines a large healthcare system with strong pharmaceutical manufacturing and hospital procurement infrastructure. The country's market is therefore positioned around established injectable therapies and efficient generic distribution. Broader bone-health competition is also increasing. In July 2025, Fresenius Kabi received European Commission approval for its denosumab biosimilars Conexxence and Bomyntra, expanding access to lower-cost bone-health biologics. Although these products are not Paget disease treatments, their entry increases competition within adjacent bone-health portfolios and may influence procurement and provider relationships.

Asia Pacific Paget Disease Treatment Market Trends

Asia Pacific is the fastest-growing regional market, driven by population aging, improving healthcare access, expanding diagnostics, and pharmaceutical manufacturing. Growth reflects increasing treatment access from a relatively low existing base, as Paget disease remains uncommon across many Asian populations.

China Paget Disease Treatment Market Trends

China offers substantial long-term potential because approximately 402 million people aged 60 and older are expected by 2040, representing around 28% of the population. Expanding hospital capacity and pharmaceutical manufacturing can improve access to diagnosis and treatment. The National Medical Products Administration regulates drug registration, safety, and standards, creating an increasingly structured environment for pharmaceutical expansion.

India Paget Disease Treatment Market Trends

India represents a particularly attractive combination of domestic demand and manufacturing capability. The country had approximately 156.7 million people aged 60 and older in 2024, with the share projected to reach about 21% by 2050. Its large generic pharmaceutical industry supports affordable production of bisphosphonates and injectable medicines. Government-backed expansion of pharmaceutical and API manufacturing further strengthens the country's potential as both a treatment market and export base. Companies serving broader bone-health portfolios can use established manufacturing and distribution networks to reach Paget disease patients without relying exclusively on this low-prevalence indication.

The global paget disease treatment market has a fragmented company structure but concentrated therapeutic economics. Company-specific market shares are generally not disclosed because pharmaceutical manufacturers typically report revenue across broader portfolios rather than separately identifying Paget disease sales. Competition is therefore concentrated around product availability, manufacturing efficiency, regulatory approvals, pricing, hospital procurement, and broader bone-health portfolios.

Leading companies emphasize generic price competitiveness, reliable injectable supply, manufacturing scale, regulatory compliance, and portfolio diversification. Market participants increasingly combine established medicines with broader bone-health products, biosimilars, specialty distribution, and local manufacturing. Differentiation depends on product availability, hospital relationships, geographic coverage, and the ability to maintain consistent quality and supply.

Key Industry Developments

• In July 2025, Fresenius received European Commission approval for its denosumab biosimilars Conexxence® and Bomyntra® in Europe.
• In February 2025, Fresenius Kabi introduced Calcitonin Salmon Injection, USP Synthetic in the United States for the treatment of symptomatic Paget’s disease of bone when alternative treatments are unsuitable.